Rossmore Private Capital Has $1.15 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Rossmore Private Capital reduced its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.8% in the 4th quarter, HoldingsChannel reports. The fund owned 4,008 shares of the medical research company’s stock after selling 115 shares during the period. Rossmore Private Capital’s holdings in Amgen were worth $1,154,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Briaud Financial Planning Inc bought a new stake in Amgen in the third quarter valued at approximately $26,000. BOK Financial Private Wealth Inc. acquired a new position in shares of Amgen in the 4th quarter worth approximately $29,000. OFI Invest Asset Management bought a new stake in shares of Amgen in the 3rd quarter valued at $26,000. Planned Solutions Inc. acquired a new stake in shares of Amgen during the fourth quarter worth $30,000. Finally, Delos Wealth Advisors LLC raised its stake in Amgen by 2,500.0% during the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after buying an additional 100 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

AMGN stock opened at $310.15 on Friday. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42. The business has a 50-day simple moving average of $277.62 and a two-hundred day simple moving average of $282.40. The company has a market capitalization of $166.37 billion, a P/E ratio of 44.31, a price-to-earnings-growth ratio of 2.79 and a beta of 0.60. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.76 by $0.20. The company had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.45 billion. Amgen had a return on equity of 156.21% and a net margin of 12.74%. Amgen’s quarterly revenue was up 22.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.98 earnings per share. Research analysts expect that Amgen Inc. will post 19.46 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a $2.25 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 2.90%. Amgen’s dividend payout ratio is currently 128.57%.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the transaction, the senior vice president now owns 9,883 shares in the company, valued at approximately $3,094,268.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.69% of the stock is owned by insiders.

Analysts Set New Price Targets

AMGN has been the topic of a number of research analyst reports. William Blair raised shares of Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday, May 3rd. Barclays upgraded Amgen from an “underweight” rating to an “equal weight” rating and lifted their target price for the stock from $230.00 to $300.00 in a report on Friday, May 3rd. The Goldman Sachs Group increased their price target on Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. Mizuho lifted their price objective on shares of Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a research note on Thursday. Finally, Truist Financial reissued a “buy” rating and set a $320.00 target price on shares of Amgen in a research note on Friday, April 12th. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $305.65.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.